Symbols / MRK
MRK Chart
About
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Gen | Market Cap | 309.55B |
| Enterprise Value | 330.81B | Income | 18.25B | Sales | 65.01B |
| Book/sh | 20.84 | Cash/sh | 7.34 | Dividend Yield | 274.00% |
| Payout | 45.05% | Employees | — | IPO | — |
| P/E | 17.05 | Forward P/E | 12.68 | PEG | — |
| P/S | 4.76 | P/B | 5.95 | P/C | — |
| EV/EBITDA | 11.49 | EV/Sales | 5.09 | Quick Ratio | — |
| Current Ratio | — | Debt/Eq | 79.71 | LT Debt/Eq | — |
| EPS (ttm) | 7.27 | EPS next Y | 9.78 | EPS Growth | -19.30% |
| Revenue Growth | 5.00% | Earnings | 2026-04-30 | ROA | — |
| ROE | 37.17% | ROIC | — | Gross Margin | 77.08% |
| Oper. Margin | 32.56% | Profit Margin | 28.08% | Shs Outstand | 2.48B |
| Shs Float | 2.48B | Short Float | 1.29% | Short Ratio | 2.37 |
| Short Interest | — | 52W High | 124.84 | 52W Low | 73.31 |
| Beta | 0.30 | Avg Volume | 13.87M | Volume | 6.61M |
| Target Price | $126.00 | Recom | Buy | Prev Close | $123.82 |
| Price | $123.93 | Change | 0.09% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$126.00
Mean price target
2. Current target
$123.93
Latest analyst target
3. DCF / Fair value
$109.05
Fallback: EPS × 15 (assumed fair P/E). No FCF data; use with …
Ratings
Current target
$123.93
Low
$100.00
High
$150.00
Mean
$126.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-25 | init | RBC Capital | — → Outperform | $142 |
| 2026-02-20 | init | Barclays | — → Overweight | $140 |
| 2026-02-06 | main | Guggenheim | Buy → Buy | $140 |
| 2026-02-04 | main | Citigroup | Neutral → Neutral | $120 |
| 2026-02-04 | main | Cantor Fitzgerald | Neutral → Neutral | $120 |
| 2026-02-04 | main | Wells Fargo | Overweight → Overweight | $135 |
| 2026-01-27 | main | Citigroup | Neutral → Neutral | $115 |
| 2026-01-20 | main | TD Cowen | Hold → Hold | $120 |
| 2026-01-08 | up | Wolfe Research | Peer Perform → Outperform | $135 |
| 2026-01-07 | main | UBS | Buy → Buy | $130 |
| 2026-01-07 | main | Citigroup | Neutral → Neutral | $110 |
| 2025-12-18 | up | BMO Capital | Market Perform → Outperform | $130 |
| 2025-12-15 | main | B of A Securities | Buy → Buy | $120 |
| 2025-12-12 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $102 |
| 2025-12-04 | main | Scotiabank | Sector Outperform → Sector Outperform | $120 |
| 2025-12-02 | main | Goldman Sachs | Buy → Buy | $120 |
| 2025-11-24 | up | Wells Fargo | Equal-Weight → Overweight | $125 |
| 2025-11-18 | main | Deutsche Bank | Hold → Hold | $111 |
| 2025-11-03 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $100 |
| 2025-09-17 | down | Berenberg | Buy → Hold | $90 |
News
RSS: Latest MRK news- Has Merck (MRK) Run Too Far After Its 41% Discount To Estimated Fair Value? - Yahoo Finance Wed, 25 Feb 2026 08
- Merck & Co., Inc. $MRK Shares Sold by RWA Wealth Partners LLC - MarketBeat Wed, 25 Feb 2026 12
- RBC Capital initiates Merck stock with outperform rating on pipeline - Investing.com ue, 24 Feb 2026 22
- Merck Reorganizes Human Health To Shape Life After Keytruda - simplywall.st Wed, 25 Feb 2026 06
- Merck CFO and R&D chief join TD Cowen health care fireside chat - Stock Titan ue, 24 Feb 2026 11
- Will Merck's Light 2026 Guide Overshadow Its Quarter Beat? - Investor's Business Daily ue, 03 Feb 2026 08
- How Is Merck & Co.'s Stock Performance Compared to Other Healthcare Stocks? - Barchart.com ue, 24 Feb 2026 16
- Could Merck Stock Quietly Help Turn Steady Dividends Into a Millionaire Retirement? - The Motley Fool Sun, 22 Feb 2026 16
- Merck: Why Investors Should Remain Bullish Despite Patent Risks - Seeking Alpha Sun, 22 Feb 2026 13
- Merck Creates Separate Cancer Business. The Stock Is Rising Ahead of Patent Cliff. - Barron's Mon, 23 Feb 2026 14
- Merck & Company, Inc. (MRK) Stock Analysis: Analyst Ratings Signal Strong Buy Potential Amidst Robust Growth - DirectorsTalk Interviews Mon, 23 Feb 2026 19
- Pharma Stock's Ascension Stalled Out - Schaeffer's Investment Research Fri, 20 Feb 2026 07
- Could Merck Stock Quietly Help Turn Steady Dividends Into a Millionaire Retirement? - Nasdaq Sun, 22 Feb 2026 16
- Merck & Company Stock Forecast 2026–2030 | Future Outlook - Capital.com Wed, 18 Feb 2026 13
- Royal Bank Of Canada Initiates Coverage on Merck & Co., Inc. (NYSE:MRK) - MarketBeat Wed, 25 Feb 2026 13
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 10000 | 1214562.0 | — | Sale at price 121.46 per share. | GUINDO CHIRFI | Officer | — | 2026-02-12 00:00:00 | D |
| 1 | 10235 | 1202844.0 | — | Sale at price 117.52 per share. | LI DEAN Y | Officer | — | 2026-02-10 00:00:00 | D |
| 2 | 10000 | 1184101.0 | — | Sale at price 118.41 per share. | GUINDO CHIRFI | Officer | — | 2026-02-09 00:00:00 | D |
| 3 | 121573 | 14485690.0 | — | Sale at price 119.15 per share. | ZACHARY JENNIFER L | General Counsel | — | 2026-02-09 00:00:00 | D |
| 4 | 121573 | 14485690.0 | — | Conversion of Exercise of derivative security at price 119.15 per share. | ZACHARY JENNIFER L | General Counsel | — | 2026-02-09 00:00:00 | D |
| 5 | 5000 | 609525.0 | — | Sale at price 121.90 per share. | WILLIAMS DAVID MICHAEL | Chief Technology Officer | — | 2026-02-06 00:00:00 | D |
| 6 | 5000 | 388100.0 | — | Conversion of Exercise of derivative security at price 77.62 per share. | WILLIAMS DAVID MICHAEL | Chief Technology Officer | — | 2026-02-06 00:00:00 | D |
| 7 | 15000 | 1827992.0 | — | Sale at price 121.87 per share. | OOSTHUIZEN JOHANNES JACOBUS | Officer | — | 2026-02-06 00:00:00 | D |
| 8 | 37685 | 4557025.0 | — | Sale at price 120.92 per share. | DELUCA RICHARD ROBERT JR. | Officer | — | 2026-02-06 00:00:00 | D |
| 9 | 20000 | 2437676.0 | — | Sale at price 121.88 per share. | GUINDO CHIRFI | Officer | — | 2026-02-05 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -73.60M | -132.09M | -233.18M | 107.62M |
| TaxRateForCalcs | 0.14 | 0.21 | 0.12 | 0.11 |
| NormalizedEBITDA | 26.23B | 7.54B | 23.31B | 16.92B |
| TotalUnusualItems | -522.00M | -629.00M | -1.99B | 982.00M |
| TotalUnusualItemsExcludingGoodwill | -522.00M | -629.00M | -1.99B | 982.00M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 17.12B | 365.00M | 14.52B | 13.05B |
| ReconciledDepreciation | 4.50B | 3.87B | 3.91B | 3.21B |
| ReconciledCostOfRevenue | 15.19B | 16.13B | 17.41B | 13.63B |
| EBITDA | 25.71B | 6.91B | 21.32B | 17.90B |
| EBIT | 21.21B | 3.04B | 17.41B | 14.69B |
| NetInterestIncome | -856.00M | -781.00M | -805.00M | -770.00M |
| InterestExpense | 1.27B | 1.15B | 962.00M | 806.00M |
| InterestIncome | 415.00M | 365.00M | 157.00M | 36.00M |
| NormalizedIncome | 17.57B | 861.91M | 16.28B | 12.17B |
| NetIncomeFromContinuingAndDiscontinuedOperation | 17.12B | 365.00M | 14.52B | 13.05B |
| TotalExpenses | 43.95B | 57.16B | 41.00B | 35.51B |
| DilutedAverageShares | 2.51B | 2.54B | 2.61B | 2.54B |
| BasicAverageShares | 2.48B | 2.53B | 2.61B | 2.53B |
| DilutedEPS | 7.28 | 6.74 | 0.14 | 5.71 |
| BasicEPS | 7.35 | 6.77 | 0.14 | 5.73 |
| DilutedNIAvailtoComStockholders | 17.12B | 365.00M | 14.52B | 13.05B |
| NetIncomeCommonStockholders | 17.12B | 365.00M | 14.52B | 13.05B |
| NetIncome | 17.12B | 365.00M | 14.52B | 13.05B |
| MinorityInterests | -16.00M | -12.00M | -7.00M | 691.00M |
| NetIncomeIncludingNoncontrollingInterests | 17.13B | 377.00M | 14.53B | 12.36B |
| NetIncomeDiscontinuousOperations | 0.00 | 0.00 | 704.00M | |
| NetIncomeContinuousOperations | 17.13B | 377.00M | 14.53B | 12.36B |
| TaxProvision | 2.80B | 1.51B | 1.92B | 1.52B |
| PretaxIncome | 19.94B | 1.89B | 16.44B | 13.88B |
| OtherIncomeExpense | 571.00M | -284.00M | -1.03B | 1.45B |
| OtherNonOperatingIncomeExpenses | 1.09B | 345.00M | 960.00M | 468.00M |
| SpecialIncomeCharges | -309.00M | -599.00M | -337.00M | -661.00M |
| RestructuringAndMergernAcquisition | 309.00M | 599.00M | 337.00M | 661.00M |
| GainOnSaleOfSecurity | -213.00M | -30.00M | -1.66B | 1.64B |
| NetNonOperatingInterestIncomeExpense | -856.00M | -781.00M | -805.00M | -770.00M |
| InterestExpenseNonOperating | 1.27B | 1.15B | 962.00M | 806.00M |
| InterestIncomeNonOperating | 415.00M | 365.00M | 157.00M | 36.00M |
| OperatingIncome | 20.22B | 2.95B | 18.28B | 13.20B |
| OperatingExpense | 28.75B | 41.03B | 23.59B | 21.88B |
| ResearchAndDevelopment | 17.94B | 30.53B | 13.55B | 12.24B |
| SellingGeneralAndAdministration | 10.82B | 10.50B | 10.04B | 9.63B |
| GrossProfit | 48.98B | 43.99B | 41.87B | 35.08B |
| CostOfRevenue | 15.19B | 16.13B | 17.41B | 13.63B |
| TotalRevenue | 64.17B | 60.12B | 59.28B | 48.70B |
| OperatingRevenue | 64.17B | 60.12B | 59.28B | 48.70B |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 1.05B | 1.05B | 1.04B | 1.05B |
| OrdinarySharesNumber | 2.53B | 2.53B | 2.54B | 2.53B |
| ShareIssued | 3.58B | 3.58B | 3.58B | 3.58B |
| NetDebt | 23.87B | 28.21B | 18.00B | 25.01B |
| TotalDebt | 37.11B | 35.05B | 30.69B | 33.10B |
| TangibleBookValue | 8.28B | -1.63B | 4.52B | -6.01B |
| InvestedCapital | 83.42B | 72.64B | 76.68B | 71.29B |
| WorkingCapital | 10.36B | 6.47B | 11.48B | 6.39B |
| NetTangibleAssets | 8.28B | -1.63B | 4.52B | -6.01B |
| CommonStockEquity | 46.31B | 37.58B | 45.99B | 38.18B |
| TotalCapitalization | 80.78B | 71.26B | 74.74B | 68.87B |
| TotalEquityGrossMinorityInterest | 46.37B | 37.63B | 46.06B | 38.26B |
| MinorityInterest | 59.00M | 54.00M | 67.00M | 73.00M |
| StockholdersEquity | 46.31B | 37.58B | 45.99B | 38.18B |
| GainsLossesNotAffectingRetainedEarnings | -4.95B | -5.16B | -4.77B | -4.43B |
| OtherEquityAdjustments | -4.95B | -5.16B | -4.77B | -4.43B |
| TreasuryStock | 58.30B | 57.45B | 56.49B | 57.11B |
| RetainedEarnings | 63.07B | 53.90B | 61.08B | 53.70B |
| AdditionalPaidInCapital | 44.70B | 44.51B | 44.38B | 44.24B |
| CapitalStock | 1.79B | 1.79B | 1.79B | 1.79B |
| CommonStock | 1.79B | 1.79B | 1.79B | 1.79B |
| TotalLiabilitiesNetMinorityInterest | 70.73B | 69.04B | 63.10B | 67.44B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 42.31B | 43.35B | 38.86B | 43.56B |
| OtherNonCurrentLiabilities | 6.46B | 8.79B | 8.32B | 9.43B |
| LiabilitiesHeldforSaleNonCurrent | 0.00 | |||
| NonCurrentDeferredLiabilities | 1.39B | 871.00M | 1.79B | 3.44B |
| NonCurrentDeferredTaxesLiabilities | 1.39B | 871.00M | 1.79B | 3.44B |
| LongTermDebtAndCapitalLeaseObligation | 34.46B | 33.68B | 28.75B | 30.69B |
| LongTermDebt | 34.46B | 33.68B | 28.75B | 30.69B |
| CurrentLiabilities | 28.42B | 25.69B | 24.24B | 23.87B |
| CurrentDebtAndCapitalLeaseObligation | 2.65B | 1.37B | 1.95B | 2.41B |
| CurrentDebt | 2.65B | 1.37B | 1.95B | 2.41B |
| PayablesAndAccruedExpenses | 25.77B | 24.32B | 22.29B | 21.46B |
| CurrentAccruedExpenses | 15.69B | 15.77B | 14.16B | 13.86B |
| Payables | 10.08B | 8.56B | 8.13B | 7.60B |
| DividendsPayable | 2.08B | 1.99B | 1.88B | 1.77B |
| TotalTaxPayable | 3.91B | 2.65B | 1.99B | 1.22B |
| IncomeTaxPayable | 3.91B | 2.65B | 1.99B | 1.22B |
| AccountsPayable | 4.08B | 3.92B | 4.26B | 4.61B |
| TotalAssets | 117.11B | 106.67B | 109.16B | 105.69B |
| TotalNonCurrentAssets | 78.32B | 74.51B | 73.44B | 75.43B |
| OtherNonCurrentAssets | 16.04B | 12.00B | 9.53B | 11.58B |
| InvestmentsAndAdvances | 463.00M | 252.00M | 1.01B | 370.00M |
| InvestmentinFinancialAssets | 463.00M | 252.00M | ||
| TradingSecurities | 463.00M | 252.00M | ||
| GoodwillAndOtherIntangibleAssets | 38.04B | 39.21B | 41.47B | 44.20B |
| OtherIntangibleAssets | 16.37B | 18.01B | 20.27B | 22.93B |
| Goodwill | 21.67B | 21.20B | 21.20B | 21.26B |
| NetPPE | 23.78B | 23.05B | 21.42B | 19.28B |
| AccumulatedDepreciation | -19.16B | -18.27B | -17.98B | -18.19B |
| GrossPPE | 42.93B | 41.32B | 39.41B | 37.47B |
| ConstructionInProgress | 7.98B | 8.26B | 9.19B | 8.31B |
| MachineryFurnitureEquipment | 18.28B | 17.76B | 16.76B | 16.30B |
| BuildingsAndImprovements | 16.36B | 14.97B | 13.17B | 12.53B |
| LandAndImprovements | 307.00M | 326.00M | 295.00M | 326.00M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 38.78B | 32.17B | 35.72B | 30.27B |
| OtherCurrentAssets | 8.71B | 8.37B | 7.17B | 6.99B |
| AssetsHeldForSaleCurrent | 0.00 | |||
| Inventory | 6.11B | 6.36B | 5.91B | 5.95B |
| Receivables | 10.28B | 10.35B | 9.45B | 9.23B |
| AccountsReceivable | 10.28B | 10.35B | 9.45B | 9.23B |
| AllowanceForDoubtfulAccountsReceivable | -89.00M | -88.00M | -72.00M | -62.00M |
| GrossAccountsReceivable | 10.37B | 10.44B | 9.52B | 9.29B |
| CashCashEquivalentsAndShortTermInvestments | 13.69B | 7.09B | 13.19B | 8.10B |
| OtherShortTermInvestments | 447.00M | 252.00M | 498.00M | 0.00 |
| CashAndCashEquivalents | 13.24B | 6.84B | 12.69B | 8.10B |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 18.10B | 9.14B | 14.71B | 9.66B |
| RepurchaseOfCapitalStock | -1.31B | -1.35B | 0.00 | -840.00M |
| RepaymentOfDebt | -1.29B | -1.75B | -2.25B | -2.32B |
| IssuanceOfDebt | 3.60B | 5.94B | 0.00 | 7.94B |
| CapitalExpenditure | -3.37B | -3.86B | -4.39B | -4.45B |
| EndCashPosition | 13.32B | 6.91B | 12.77B | 8.17B |
| OtherCashAdjustmentOutsideChangeinCash | 0.00 | 0.00 | ||
| BeginningCashPosition | 6.91B | 12.77B | 8.17B | 8.15B |
| EffectOfExchangeRateChanges | -293.00M | 23.00M | -410.00M | -133.00M |
| ChangesInCash | 6.70B | -5.89B | 5.02B | 147.00M |
| FinancingCashFlow | -7.03B | -4.81B | -9.12B | 2.59B |
| CashFromDiscontinuedFinancingActivities | 0.00 | 0.00 | -504.00M | |
| CashFlowFromContinuingFinancingActivities | -7.03B | -4.81B | -9.12B | 3.10B |
| NetOtherFinancingCharges | -372.00M | -328.00M | -240.00M | 8.71B |
| ProceedsFromStockOptionExercised | 177.00M | 125.00M | 384.00M | 202.00M |
| CashDividendsPaid | -7.84B | -7.45B | -7.01B | -6.61B |
| CommonStockDividendPaid | -7.84B | -7.45B | -7.01B | -6.61B |
| NetCommonStockIssuance | -1.31B | -1.35B | 0.00 | -840.00M |
| CommonStockPayments | -1.31B | -1.35B | 0.00 | -840.00M |
| NetIssuancePaymentsOfDebt | 2.31B | 4.18B | -2.25B | 1.63B |
| NetShortTermDebtIssuance | 0.00 | 0.00 | -3.99B | |
| NetLongTermDebtIssuance | 2.31B | 4.18B | -2.25B | 5.62B |
| LongTermDebtPayments | -1.29B | -1.75B | -2.25B | -2.32B |
| LongTermDebtIssuance | 3.60B | 5.94B | 0.00 | 7.94B |
| InvestingCashFlow | -7.73B | -14.08B | -4.96B | -16.55B |
| CashFromDiscontinuedInvestingActivities | 0.00 | 0.00 | -134.00M | |
| CashFlowFromContinuingInvestingActivities | -7.73B | -14.08B | -4.96B | -16.42B |
| NetOtherInvestingChanges | -127.00M | -36.00M | -89.00M | -91.00M |
| NetInvestmentPurchaseAndSale | -142.00M | 1.85B | -483.00M | 1.02B |
| SaleOfInvestment | 377.00M | 2.80B | 721.00M | 1.03B |
| PurchaseOfInvestment | -519.00M | -955.00M | -1.20B | -1.00M |
| NetBusinessPurchaseAndSale | -4.09B | -12.03B | 0.00 | -12.91B |
| PurchaseOfBusiness | -4.09B | -12.03B | 0.00 | -12.91B |
| CapitalExpenditureReported | -3.37B | -3.86B | -4.39B | -4.45B |
| OperatingCashFlow | 21.47B | 13.01B | 19.09B | 14.11B |
| CashFromDiscontinuedOperatingActivities | 0.00 | 0.00 | 987.00M | |
| CashFlowFromContinuingOperatingActivities | 21.47B | 13.01B | 19.09B | 13.12B |
| ChangeInWorkingCapital | -3.67B | -2.21B | -2.78B | -3.84B |
| ChangeInOtherWorkingCapital | -1.42B | -2.31B | -1.47B | -1.76B |
| ChangeInOtherCurrentLiabilities | -49.00M | 456.00M | -545.00M | 484.00M |
| ChangeInPayablesAndAccruedExpense | -1.12B | 1.62B | 41.00M | 142.00M |
| ChangeInAccruedExpense | -2.33B | 1.78B | -50.00M | 277.00M |
| ChangeInPayable | 1.21B | -166.00M | 91.00M | -135.00M |
| ChangeInAccountPayable | 182.00M | -380.00M | -289.00M | 405.00M |
| ChangeInTaxPayable | 1.02B | 214.00M | 380.00M | -540.00M |
| ChangeInIncomeTaxPayable | 1.02B | 214.00M | 380.00M | -540.00M |
| ChangeInInventory | -835.00M | -816.00M | -161.00M | -674.00M |
| ChangeInReceivables | -244.00M | -1.15B | -644.00M | -2.03B |
| ChangesInAccountReceivables | -244.00M | -1.15B | -644.00M | -2.03B |
| OtherNonCashItems | 3.97B | 11.76B | 1.30B | 2.36B |
| StockBasedCompensation | 761.00M | 645.00M | 541.00M | 479.00M |
| AssetImpairmentCharge | 39.00M | 792.00M | 1.75B | 302.00M |
| DeferredTax | -1.25B | -1.90B | -1.57B | 187.00M |
| DeferredIncomeTax | -1.25B | -1.90B | -1.57B | 187.00M |
| DepreciationAmortizationDepletion | 4.50B | 3.87B | 3.91B | 3.21B |
| DepreciationAndAmortization | 4.50B | 3.87B | 3.91B | 3.21B |
| AmortizationCashFlow | 2.40B | 2.04B | 2.08B | 1.64B |
| AmortizationOfIntangibles | 2.40B | 2.04B | 2.08B | 1.64B |
| Depreciation | 2.10B | 1.83B | 1.82B | 1.58B |
| OperatingGainsLosses | -14.00M | -340.00M | 1.42B | -1.94B |
| EarningsLossesFromEquityInvestments | -340.00M | 1.42B | -1.94B | |
| GainLossOnInvestmentSecurities | -14.00M | -340.00M | 1.42B | -1.94B |
| NetIncomeFromContinuingOperations | 17.13B | 377.00M | 14.53B | 12.36B |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for MRK
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|